Histology
Mucinous Neoplasm
CI-CAN-00001237Explore in graph →
Non-malignant37 active trials4 evidence items
- NCIt
- C7070
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001237Explore in graph →
Clinical trials
178 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib(DURAFAK) | recruiting | Phase 2 | 55 | University of OklahomaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT07216521 |
| Intent of Surgery for IPMN |
| recruiting |
| — |
| 2,000 |
| NYU Langone HealthOTHER |
| 5 |
| Oct 14, 2025 |
| clinicaltrials |
| NCT06574373 | Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression | recruiting | — | 3,600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07117045 | Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer(AI-LDCT-PC) | recruiting | — | 400,000 | Changhai HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | terminated | N/A | 77 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07014709 | Impact of GLP-1 Receptor Agonists on Patients With IPMN(IPMN-GLP1RA) | not yet recruiting | — | 30 | Hôpital FribourgeoisOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05734430 | Genetics of Appendix Cancer Study(GAP) | recruiting | — | 700 | Andreana Holowatyj, PhD, MSCIOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06638866 | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort(AI-PANC) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06570174 | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients | completed | N/A | 60 | Yonsei UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02132858 | Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation | completed | — | 43 | Fox Chase Cancer CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06283576 | Pancreatic Cancer Initial Detection Via Liquid Biopsy(PANCAID) | enrolling by invitation | — | 200 | Karolinska University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05117723 | Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer(MAPS) | recruiting | — | 1,000 | St Vincent's Hospital MelbourneOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02232152 | CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 19 | Wake Forest University Health SciencesOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05513183 | Severe Neutropenia After HIPEC Using Mitomycin-C | completed | — | 74 | Gangnam Severance HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT02599116 | Gastrointestinal Microbiome Study of Appendiceal Cancer | unknown | N/A | 24 | Mercy Medical CenterOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05433935 | Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05593393 | A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm | unknown | — | 1,500 | Peking Union Medical College HospitalOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03731819 | Establishment of Abbreviated Pancreatobiliary MRI Protocol | completed | N/A | 30 | Seoul National University HospitalOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT01643460 | Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts | completed | N/A | 33 | Indiana UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03305146 | Feasibility of Molecular Biology in Pancreatic Cyst Tumors(CYST-GEN) | active not recruiting | N/A | 93 | Hospital St. Joseph, Marseille, FranceOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Oct 31, 2025source: clinicaltrials